Previous 10 | Next 10 |
home / stock / mdnaf / mdnaf news
TORONTO and HOUSTON , June 19, 2019 /PRNewswire/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA; OTCQB: MDNAF), a clinical stage immuno-oncology company, is pleased to announce that Dr. Fahar Merchant, Chairman, President and CEO will present an overv...
Medicenna Presents Preliminary Top-Line Clinical Results from their Phase 2b Trial of MDNA55 in Recurrent Glioblastoma Canada NewsWire TORONTO and HOUSTON, June 18, 2019 - Disease control rate of up to 83% achieved; evidence of improved survival for patients TORONTO ...
Medicenna To Host Key Opinion Leader Call Focused on MDNA55 Recurrent Glioblastoma Program and Preliminary Top-Line Results Canada NewsWire TORONTO and HOUSTON, June 13, 2019 TORONTO and HOUSTON , June 13, 2019 / CNW/ - Medicenna Therapeutics Corp. (" Medicenna "...
TORONTO and HOUSTON , June 5, 2019 /PRNewswire/ - Medicenna Therapeutics Corp. (" Medicenna " or "the Company ") (TSX: MDNA, OTCQB: MDNAF), a clinical stage Immuno-Oncology company, today announced that it will present preliminary top-line results from the recently completed Phas...
75% of IL4R +ve Patients Achieve Disease Control Following One Treatment With MDNA55 TORONTO and HOUSTON, TX , June 3, 2019 /PRNewswire/ - Medicenna Therapeutics Corp. (" Medicenna " or "the Company ") (TSX: MDNA, OTCQB: MDNAF), a clinical stage immunotherapy company develop...
Medicenna to Present at the 9th Annual LD Micro Invitational Canada NewsWire TORONTO and HOUSTON, TX, May 30, 2019 TORONTO and HOUSTON, TX, May 30, 2019 /CNW/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA; OTCQB: MDNAF), a clinical st...
Medicenna Announces Upcoming Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting Canada NewsWire TORONTO and HOUSTON, May 16, 2019 TORONTO and HOUSTON , May 16, 2019 /CNW/ - Medicenna Therapeutics Corp. (" Medicenna " or "the Company "...
TORONTO and HOUSTON , May 1, 2019 /PRNewswire/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA; OTCQB: MDNAF), a clinical stage immuno-oncology company, announced today that it has received US$757,940 (approximately, CD$1.02M) from the Cancer Prevention and Re...
Interim Top-Line Results to be Announced in June, 2019 TORONTO and HOUSTON , April 30, 2019 /PRNewswire/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA; OTCQB: MDNAF), a clinical stage immuno-oncology company, is pleased to announce that it has completed enro...
TORONTO , ON and HOUSTON, TX , April 23, 2019 /PRNewswire/ - Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA; OTCQB: MDNAF), a clinical stage immuno-oncology company, is pleased to announce that executives from Medicenna, Dr. Fahar Merchant, Chairman...
News, Short Squeeze, Breakout and More Instantly...
Increased cash balance to $37 million following a $20 million investment by RA Capital extending runway into mid-2026 MDNA11 continues to exhibit compelling deep and durable single agent activity and best-in-class potential relative to other IL-2 therapies in clinical development ...
- ABILITY-1 study is currently enrolling patients for the treatment of advanced solid tumors with MDNA11, a novel long-acting IL-2 super-agonist, as a monotherapy or in combination with KEYTRUDA ® , at clinical trial sites in U.S.A., Canada, Australia, and Korea - Monot...
Single treatment with bizaxofusp achieved significant survival benefit (mOS of 13.5 vs. 7.2 months, p=0.009) and reduced risk of death by almost half ( hazard ratio: 0.54, 95% confidence interval: 0.34-0.83) versus a propensity balanced external control (EC) arm irrespective of IL...